# ClinicalTrials.gov record NCT07684235

> PeptideScanner retained ClinicalTrials.gov record NCT07684235 at 2026-08-13T05:52:27.017Z. Its registry update date was 2026-08-04, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.

- Evidence object: `story:clinicaltrials-gov-nct07684235-maridebart-cafraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-04
- Source checked: 2026-08-13
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07684235-maridebart-cafraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct07684235-maridebart-cafraglutide-v1.json
- Content SHA-256: `2c8faffc901d2fc1c2617e5bd1e8f234d814c20cb6fe6521c084033cc655244b`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT07684235 ([`ctg-observation-nct07684235-2026-08-04-8fc86edf161b`](#source-ctg-observation-nct07684235-2026-08-04-8fc86edf161b))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07684235 at 2026-08-13T05:52:27.017Z. Its registry update date was 2026-08-04, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide. ([`ctg-observation-nct07684235-2026-08-04-8fc86edf161b`](#source-ctg-observation-nct07684235-2026-08-04-8fc86edf161b))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07684235 at 2026-08-13T05:52:27.017Z. Its registry update date was 2026-08-04, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide. ([`ctg-observation-nct07684235-2026-08-04-8fc86edf161b`](#source-ctg-observation-nct07684235-2026-08-04-8fc86edf161b))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07684235-2026-08-04-8fc86edf161b`](#source-ctg-observation-nct07684235-2026-08-04-8fc86edf161b))

## Sources

<a id="source-ctg-observation-nct07684235-2026-08-04-8fc86edf161b"></a>
- **ClinicalTrials.gov record NCT07684235 · retained source version 2026-08-04:8fc86edf161b19dd348d2fed7847cdbde4ce7abb7d1b1d08beb9b11fb77b82de** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07684235) (`ctg-observation-nct07684235-2026-08-04-8fc86edf161b`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07684235." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct07684235-maridebart-cafraglutide-v1.json SHA-256: 2c8faffc901d2fc1c2617e5bd1e8f234d814c20cb6fe6521c084033cc655244b.